These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 29333665)

  • 1. Clinical and metabolic effects associated with weight changes and obeticholic acid in non-alcoholic steatohepatitis.
    Hameed B; Terrault NA; Gill RM; Loomba R; Chalasani N; Hoofnagle JH; Van Natta ML;
    Aliment Pharmacol Ther; 2018 Mar; 47(5):645-656. PubMed ID: 29333665
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of obeticholic acid on the lipoprotein profile in patients with non-alcoholic steatohepatitis.
    Siddiqui MS; Van Natta ML; Connelly MA; Vuppalanchi R; Neuschwander-Tetri BA; Tonascia J; Guy C; Loomba R; Dasarathy S; Wattacheril J; Chalasani N; Sanyal AJ;
    J Hepatol; 2020 Jan; 72(1):25-33. PubMed ID: 31634532
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Non-invasive evaluation of response to obeticholic acid in patients with NASH: Results from the REGENERATE study.
    Rinella ME; Dufour JF; Anstee QM; Goodman Z; Younossi Z; Harrison SA; Loomba R; Sanyal AJ; Bonacci M; Trylesinski A; Natha M; Shringarpure R; Granston T; Venugopal A; Ratziu V
    J Hepatol; 2022 Mar; 76(3):536-548. PubMed ID: 34793868
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial.
    Neuschwander-Tetri BA; Loomba R; Sanyal AJ; Lavine JE; Van Natta ML; Abdelmalek MF; Chalasani N; Dasarathy S; Diehl AM; Hameed B; Kowdley KV; McCullough A; Terrault N; Clark JM; Tonascia J; Brunt EM; Kleiner DE; Doo E;
    Lancet; 2015 Mar; 385(9972):956-65. PubMed ID: 25468160
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease.
    Mudaliar S; Henry RR; Sanyal AJ; Morrow L; Marschall HU; Kipnes M; Adorini L; Sciacca CI; Clopton P; Castelloe E; Dillon P; Pruzanski M; Shapiro D
    Gastroenterology; 2013 Sep; 145(3):574-82.e1. PubMed ID: 23727264
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Obeticholic acid raises LDL-cholesterol and reduces HDL-cholesterol in the Diet-Induced NASH (DIN) hamster model.
    Briand F; Brousseau E; Quinsat M; Burcelin R; Sulpice T
    Eur J Pharmacol; 2018 Jan; 818():449-456. PubMed ID: 29155143
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factors Associated With Histologic Response in Adult Patients With Nonalcoholic Steatohepatitis.
    Loomba R; Sanyal AJ; Kowdley KV; Terrault N; Chalasani NP; Abdelmalek MF; McCullough AJ; Shringarpure R; Ferguson B; Lee L; Chen J; Liberman A; Shapiro D; Neuschwander-Tetri BA
    Gastroenterology; 2019 Jan; 156(1):88-95.e5. PubMed ID: 30222962
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CONTROL: A randomized phase 2 study of obeticholic acid and atorvastatin on lipoproteins in nonalcoholic steatohepatitis patients.
    Pockros PJ; Fuchs M; Freilich B; Schiff E; Kohli A; Lawitz EJ; Hellstern PA; Owens-Grillo J; Van Biene C; Shringarpure R; MacConell L; Shapiro D; Cohen DE
    Liver Int; 2019 Nov; 39(11):2082-2093. PubMed ID: 31402538
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Superior reductions in hepatic steatosis and fibrosis with co-administration of a glucagon-like peptide-1 receptor agonist and obeticholic acid in mice.
    Jouihan H; Will S; Guionaud S; Boland ML; Oldham S; Ravn P; Celeste A; Trevaskis JL
    Mol Metab; 2017 Nov; 6(11):1360-1370. PubMed ID: 29107284
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Obeticholic acid-a new therapy in PBC and NASH.
    Chapman RW; Lynch KD
    Br Med Bull; 2020 May; 133(1):95-104. PubMed ID: 32282030
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multicenter Validation of Association Between Decline in MRI-PDFF and Histologic Response in NASH.
    Loomba R; Neuschwander-Tetri BA; Sanyal A; Chalasani N; Diehl AM; Terrault N; Kowdley K; Dasarathy S; Kleiner D; Behling C; Lavine J; Van Natta M; Middleton M; Tonascia J; Sirlin C;
    Hepatology; 2020 Oct; 72(4):1219-1229. PubMed ID: 31965579
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect and safety of obeticholic acid for patients with nonalcoholic steatohepatitis: A systematic review and meta-analysis of randomized controlled trials.
    Zhao J; Li B; Zhang K; Zhu Z
    Medicine (Baltimore); 2024 Feb; 103(7):e37271. PubMed ID: 38363900
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial.
    Younossi ZM; Ratziu V; Loomba R; Rinella M; Anstee QM; Goodman Z; Bedossa P; Geier A; Beckebaum S; Newsome PN; Sheridan D; Sheikh MY; Trotter J; Knapple W; Lawitz E; Abdelmalek MF; Kowdley KV; Montano-Loza AJ; Boursier J; Mathurin P; Bugianesi E; Mazzella G; Olveira A; Cortez-Pinto H; Graupera I; Orr D; Gluud LL; Dufour JF; Shapiro D; Campagna J; Zaru L; MacConell L; Shringarpure R; Harrison S; Sanyal AJ;
    Lancet; 2019 Dec; 394(10215):2184-2196. PubMed ID: 31813633
    [TBL] [Abstract][Full Text] [Related]  

  • 14. REGENERATE: Design of a pivotal, randomised, phase 3 study evaluating the safety and efficacy of obeticholic acid in patients with fibrosis due to nonalcoholic steatohepatitis.
    Ratziu V; Sanyal AJ; Loomba R; Rinella M; Harrison S; Anstee QM; Goodman Z; Bedossa P; MacConell L; Shringarpure R; Shah A; Younossi Z
    Contemp Clin Trials; 2019 Sep; 84():105803. PubMed ID: 31260793
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized, placebo-controlled, phase II study of obeticholic acid for primary sclerosing cholangitis.
    Kowdley KV; Vuppalanchi R; Levy C; Floreani A; Andreone P; LaRusso NF; Shrestha R; Trotter J; Goldberg D; Rushbrook S; Hirschfield GM; Schiano T; Jin Y; Pencek R; MacConell L; Shapiro D; Bowlus CL;
    J Hepatol; 2020 Jul; 73(1):94-101. PubMed ID: 32165251
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid.
    Hirschfield GM; Mason A; Luketic V; Lindor K; Gordon SC; Mayo M; Kowdley KV; Vincent C; Bodhenheimer HC; Parés A; Trauner M; Marschall HU; Adorini L; Sciacca C; Beecher-Jones T; Castelloe E; Böhm O; Shapiro D
    Gastroenterology; 2015 Apr; 148(4):751-61.e8. PubMed ID: 25500425
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased hepatoprotective effects of the novel farnesoid X receptor agonist INT-787 versus obeticholic acid in a mouse model of nonalcoholic steatohepatitis.
    Adorini L; Rigbolt K; Feigh M; Roth J; Erickson M
    PLoS One; 2024; 19(4):e0300809. PubMed ID: 38662778
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolic and hepatic effects of liraglutide, obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis.
    Tølbøl KS; Kristiansen MN; Hansen HH; Veidal SS; Rigbolt KT; Gillum MP; Jelsing J; Vrang N; Feigh M
    World J Gastroenterol; 2018 Jan; 24(2):179-194. PubMed ID: 29375204
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship between three commonly used non-invasive fibrosis biomarkers and improvement in fibrosis stage in patients with non-alcoholic steatohepatitis.
    Chalasani N; Abdelmalek MF; Loomba R; Kowdley KV; McCullough AJ; Dasarathy S; Neuschwander-Tetri BA; Terrault N; Ferguson B; Shringarpure R; Shapiro D; Sanyal AJ
    Liver Int; 2019 May; 39(5):924-932. PubMed ID: 30253043
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of obeticholic acid in liver disease-A systematic review and meta-analysis.
    Kulkarni AV; Tevethia HV; Arab JP; Candia R; Premkumar M; Kumar P; Sharma M; Reddy DN; Padaki NR
    Clin Res Hepatol Gastroenterol; 2021 May; 45(3):101675. PubMed ID: 33722778
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.